This page is available in multiple languages
Select Language

Medesis Pharma lists successfully on Euronext Growth to launch several phase II clinical trials



Paris 12 February 2021 – Euronext today congratulates the biotech company Medesis Pharma from Montpellier for its listing on Euronext Growth Paris (ticker code: ALMDP).

Founded in 2003, Medesis Pharma has developed a technology that allows the oral administration of active pharmaceutical ingredients, with the aim of addressing serious diseases for which there is no effective treatment. The biotech company goes public today in order to accelerate its development thanks to new recruitments, new collaborative programmes, and the realisation of at least three phase II clinical trials in 2021.

Medesis Pharma was listed through the admission to trading of the 4,357,453 shares making up its equity, of which 1,087,773 new shares were issued under a Global Offering[1], including the full exercise of the extension clause and the exercise of the over-allotment option.

The admission and issue price of Medesis Pharma shares was set at €6.76 per share. Market capitalisation was €29.5 million on the day of listing. The offering raised €7.4 million altogether.

The offering was a resounding success with international institutional and individual investors, with a global oversubscription rate of 7.4 times. At €35.5 million, the demand for the public offering underlines the strong appetite of individual investors in the current context.

Jean-Claude Maurel, CEO and founder of Medesis Pharma said: "We are pleased with the great success of Medesis Pharma's IPO and thank all the investors, both institutional and individual, who have placed their trust in us through this transaction. Medesis Pharma now has the means to accelerate its development by launching clinical trials on its main programmes and thus move closer to its objective, which is to treat serious diseases that currently lack effective treatments.”

Medesis Pharma

Caption: Camille Leca, Euronext’s Chief Operating Officer Listing and Head of Listing in France, rang the bell during a virtual ceremony this morning with Jean-Claude Maurel, CEO and founder of Medesis Pharma, and his team, to celebrate the Initial Public Offering of the company.


About Medesis Pharma In order to advance in the treatment of serious diseases for which there is no effective treatment, Medesis Pharma is developing drug candidates based on its proprietary Aonys® technology for the delivery of active ingredients in the form of nanodroplets by mouth, which makes the delivery of the active ingredients to all cells effective, with the passage of the Hemato-encephalic Barrier. This innovative approach is being applied to future drugs to treat major diseases such as Alzheimer's disease, Huntington's disease, certain resistant cancers and severe respiratory inflammation. French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 9 patents, the result of 17 years of research and is currently focusing on 4 projects entering Phase II clinical trials in the field of neurodegenerative diseases and the treatment of Covid-19. Medesis Pharma is also working on new applications of its technology in partnership with public research laboratories (CNRS, CEA, IRBA), major university hospitals in France, Canada and the United States, as well as private companies such as Transgene. For more information, please visit:

[1] The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.